MedPath

Pilocarpine

Generic Name
Pilocarpine
Brand Names
Betoptic Pilo, Isoptocarpine, Minims Pilocarpine Nitrate, Salagen, Vuity
Drug Type
Small Molecule
Chemical Formula
C11H16N2O2
CAS Number
92-13-7
Unique Ingredient Identifier
01MI4Q9DI3
Background

Pilocarpine is a cholinergic muscarinic receptor agonist.

Indication

Pilocarpine oral tablets are indicated for the treatment of dry mouth caused by Sjogren's Syndrome or radiotherapy for cancer of the head and neck.

Pilocarpine ophthalmic formulations are used to treat presbyopia in adults, reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, manage acute angle-closure glaucoma, prevent postoperative elevated IOP associated with laser surgery, and induce miosis.

Associated Conditions
Acute angle-closure glaucoma, Dry Mouth, Glaucoma, Closed-Angle, Increased Intra Ocular Pressure (IOP), Narrow-angle glaucoma, Ocular Hypertension, Open Angle Glaucoma (OAG), Presbyopia, Chronic open-angle glaucoma
Clinical Trials
Related News

A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Phase 3
Completed
Conditions
Presbyopia
Interventions
Other: Vehicle
First Posted Date
2019-02-28
Last Posted Date
2021-12-29
Lead Sponsor
Allergan
Target Recruit Count
427
Registration Number
NCT03857542
Locations
🇺🇸

Advanced Vision Care, Los Angeles, California, United States

🇺🇸

South Florida Vision Center, Fort Lauderdale, Florida, United States

🇺🇸

Eye Center South, Dothan, Alabama, United States

and more 32 locations

Pilocarpine and Brimonidine in Patients With Monofocal Lenses

Early Phase 1
Conditions
Pseudophakia
Presbyopia
Interventions
First Posted Date
2019-01-31
Last Posted Date
2019-01-31
Lead Sponsor
Massachusetts Eye and Ear Infirmary
Target Recruit Count
33
Registration Number
NCT03825081
Locations
🇺🇸

Massachusetts Eye and Ear, Boston, Massachusetts, United States

Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Phase 3
Completed
Conditions
Presbyopia
Interventions
Other: Vehicle
First Posted Date
2019-01-15
Last Posted Date
2021-12-28
Lead Sponsor
Allergan
Target Recruit Count
323
Registration Number
NCT03804268
Locations
🇺🇸

American Institute of Research, Los Angeles, California, United States

🇺🇸

Eye Research Foundation, Newport Beach, California, United States

🇺🇸

Danbury Eye Physicians and Surgeons P.C., Danbury, Connecticut, United States

and more 33 locations

Measuring Sweat Glucose of Patients With Diabetes - The ENGAGE Study

Not Applicable
Terminated
Conditions
Diabetes Mellitus
Interventions
Device: Adhesive glucose sensor
First Posted Date
2018-03-09
Last Posted Date
2020-07-09
Lead Sponsor
University of California, San Diego
Target Recruit Count
2
Registration Number
NCT03460964
Locations
🇺🇸

UCSD Altman Clinical and Translational Research Institute, San Diego, California, United States

🇺🇸

UCSD, San Diego, California, United States

Effect of Pilocarpine in Patients With Xerostomia

Phase 4
Conditions
Xerostomia
Interventions
Other: Spray without Pilocarpine
First Posted Date
2016-12-05
Last Posted Date
2016-12-05
Lead Sponsor
University of Sao Paulo
Target Recruit Count
80
Registration Number
NCT02982577
Locations
🇧🇷

University of São Paulo, Ribeirao Preto, São Paulo, Brazil

Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat

Not Applicable
Completed
Conditions
Stability & Variability of Lipid-derived Molecules in Sweat
Interventions
Other: Physiological induction of sweating
First Posted Date
2016-10-18
Last Posted Date
2018-06-01
Lead Sponsor
USDA, Western Human Nutrition Research Center
Target Recruit Count
14
Registration Number
NCT02935894
Locations
🇺🇸

Western Human Nutrition Research Center, Davis, California, United States

Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study

Not Applicable
Conditions
Glaucoma
Interventions
First Posted Date
2016-08-12
Last Posted Date
2022-04-07
Lead Sponsor
Medical University of Vienna
Target Recruit Count
90
Registration Number
NCT02865473
Locations
🇦🇹

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure

Not Applicable
Completed
Conditions
Glaucoma, Open-angle
Hypertension, Ocular
Interventions
First Posted Date
2016-04-28
Last Posted Date
2019-11-07
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
27
Registration Number
NCT02754570
Locations
🇺🇸

University of Colorado Denver Eye Hospital, Denver, Colorado, United States

Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure

Not Applicable
Conditions
Glaucoma, Angle-Closure
Interventions
Procedure: LPIP plus LPI
Procedure: LPI
First Posted Date
2015-11-24
Last Posted Date
2018-09-06
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
240
Registration Number
NCT02613013
Locations
🇨🇳

Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Placebo
First Posted Date
2015-05-18
Last Posted Date
2015-08-13
Lead Sponsor
Astellas Pharma Europe B.V.
Target Recruit Count
12
Registration Number
NCT02447315
Locations
🇬🇧

PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy